UCAR-T cells for hard-to-treat membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell therapy (called UCAR-T) that targets two proteins on immune cells to help calm the immune system and reduce kidney damage in people with a tough-to-treat form of membranous nephropathy. It’s for patients who haven’t gotten better with standard treatments and have high levels of protein leaking into their urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a kidney biopsy that shows primary membranous nephropathy (a specific type of kidney disease).
- Your kidney disease must be high-risk or not well-controlled after prior treatments (with persistent protein in urine).
- Your kidney function (eGFR) must be 45 or above if you have relapsed or treatment-resistant disease.
- You must be willing to use birth control during the study and for 6 months after (if of childbearing age).
- You cannot have certain other conditions like active infections, other cancers, severe heart disease, or uncontrolled diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a new treatment using UCAR T-cells that target CD19 and BCMA proteins, for people with autoimmune diseases like lupus or arthritis that have come back or not responded to other treatments. It aims to see if this therapy can help control the disease.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
Hear when a new Refractory Idiopathic Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.